Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endoscope-Assisted "Extended" Suturectomy for Unicoronal Craniosynostosis: A Technical Note.

Plastic and reconstructive surgery·2021

Same author

Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins.

The Cochrane database of systematic reviews·2016

Same author

Long-Term Incisal Relationships After Palatoplasty in Patients With Isolated Cleft Palate.

The Journal of craniofacial surgery·2016

Same author

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.

The Cochrane database of systematic reviews·2015

Same author

Anatomical study of the effects of five surgical maneuvers on palate movement.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2014

Same author

Endovascular repair of abdominal aortic aneurysm.

The Cochrane database of systematic reviews·2014

Search research articles

Related Experiment Video

Updated: May 8, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Beta blockers for peripheral arterial disease.

Sharath Chandra Vikram Paravastu¹, Derick A Mendonca, Anthony Da Silva

¹Academic Vascular Unit, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK, S1 4DA.

The Cochrane Database of Systematic Reviews

|September 13, 2013

Summary

This summary is machine-generated.

Beta blockers do not appear to worsen walking distance or calf blood flow in patients with peripheral arterial disease and intermittent claudication. However, caution is advised due to limited trial data.

More Related Videos

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Related Experiment Videos

Last Updated: May 8, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Area of Science:

Cardiology
Vascular Medicine
Pharmacology

Background:

Beta blockers are standard for coronary artery disease (CAD).
Their use in patients with co-existing intermittent claudication (IC) is debated due to potential peripheral hemodynamic effects.
This review is an update of prior research from 2008.

Purpose of the Study:

To assess the impact of beta blockers on walking distance and calf hemodynamics in peripheral arterial disease (PAD) patients.
Quantify effects on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance, and skin temperature.

Main Methods:

Systematic review of randomized controlled trials (RCTs) comparing beta blockers (selective and non-selective) to placebo.
Searched Cochrane Peripheral Vascular Diseases Group trials register and CENTRAL up to March 2013.
Primary outcomes: claudication and walking distances; Secondary outcomes: calf blood flow, vascular resistance, skin temperature.

Main Results:

Six low-quality RCTs with 119 participants were included.
Beta blockers studied: atenolol, propranolol, pindolol, metoprolol.
No statistically significant adverse effects on walking distance, calf blood flow, vascular resistance, or skin temperature were observed compared to placebo. No adverse events reported.

Conclusions:

Current evidence does not indicate that beta blockers negatively impact walking distance or calf hemodynamics in patients with intermittent claudication.
Due to a lack of large-scale trials, beta blockers should be used cautiously if clinically indicated for CAD patients with PAD.